Sagimet Biosciences Inc. Proceeds from Collaborators
Sagimet Biosciences Inc. (SGMT) reported Proceeds from Collaborators of $1.70 million for the 1-month period ending 2023-08-31, per its 10-Q filed 2024-11-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromCollaborators · last filed 2024-11-14
- 2023-08-31: Proceeds from Collaborators 1 month $1.70M.
| Period end | Proceeds from Collaborators 1 month |
|---|---|
| 2023-08-31 | $1.70M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |